Modified-Release Oral Minoxidil for Stable Hair Loss Dosing

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing treatments for hair loss, such as topical minoxidil, often result in rapid absorption and short duration of action, leading to fluctuating serum levels and potential adverse effects, while oral minoxidil formulations lack controlled release mechanisms to maintain effective concentrations over time.

Innovation Solution

A modified release oral formulation of minoxidil or its pharmaceutically acceptable salts, designed to release 50% to 98% of the daily dose within 12 hours, with a Tmax of 30 to 360 minutes and Cmax of 0.25 ng/ml to 20 ng/ml, providing sustained pharmacokinetic profiles to treat hair loss effectively.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Duration of action of moving object

If topical minoxidil is used for hair loss treatment, then the drug can be applied locally to the scalp, but rapid absorption occurs leading to short duration of action and fluctuating serum levels

Engineering Contradiction:

Improveduration of actionVSAvoidserum level stability

Core Design Contradiction:

Duration of action of moving objectVSStability of the object's composition

Solution Approach 1:

The patent segments the minoxidil delivery system into multiple components including a controlled-release formulation that releases the drug over time, and combines it with other active ingredients like caffeine and biotin to create a multi-component system that addresses different aspects of hair loss while maintaining stable drug levels

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent introduces intermediary substances such as penetration enhancers and controlled-release agents that mediate between the minoxidil and the scalp tissue, controlling the rate and extent of absorption to prevent rapid uptake and maintain stable serum levels

Inventive Principle:

Principle #24Intermediary (Mediator)

2Quantity of substance

If oral minoxidil formulations are used, then systemic delivery is achieved, but lack of controlled release mechanisms results in inability to maintain effective concentrations over time

Engineering Contradiction:

Improveeffective concentration maintenanceVSAvoidduration of effective concentration

Core Design Contradiction:

Quantity of substanceVSDuration of action of stationary object

Solution Approach 1:

The patent employs dynamic controlled-release mechanisms that adjust the drug release rate based on physiological conditions, using pH-sensitive and enzyme-responsive materials that modify their release characteristics in response to the gastrointestinal environment and systemic conditions

Inventive Principle:

Principle #15Dynamics

Solution Approach 2:

The patent utilizes parameter changes in the formulation including varying polymer compositions, molecular weights, and cross-linking densities to control the release kinetics of minoxidil, thereby maintaining effective concentrations over extended periods through modified release profiles

Inventive Principle:

Principle #35Parameter changes

3Speed

If rapid absorption of minoxidil occurs, then quick therapeutic effect is achieved, but adverse effects increase due to fluctuating serum levels

Engineering Contradiction:

Improveabsorption speedVSAvoidadverse effects

Core Design Contradiction:

SpeedVSObject-generated harmful factors

Solution Approach 1:

The patent implements periodic action through pulsatile release systems that deliver minoxidil in controlled intervals rather than continuous release, creating periodic peaks and troughs in drug concentration that maintain efficacy while reducing the harmful effects of sustained high levels

Inventive Principle:

Principle #19Periodic action

Solution Approach 2:

The patent converts the potentially harmful rapid absorption into a benefit by using it to trigger immediate therapeutic effect while simultaneously employing buffering systems and metabolizing agents that mitigate the adverse effects of rapid drug entry into circulation

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS20260083738A1Compositions and methods of use for modified release minoxidil

Publication Date: 2026.03.26 VERADERMICS INC

AI summary

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.